284 related articles for article (PubMed ID: 19414943)
41. Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients.
Piotr B; Mariusz S; Jacek R
Curr Pharm Biotechnol; 2017; 18(4):303-308. PubMed ID: 28137221
[TBL] [Abstract][Full Text] [Related]
42. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
[TBL] [Abstract][Full Text] [Related]
43. Effect of conversion from ESA with shorter half-life to CERA once monthly for maintaining Hb concentration in pre-dialysis CKD patients.
Choi JY; Yang CW; Kim YH; Joo KW; Yoo TH; Lee KW; Lee SH; Moon JY; Shin SK; Huh W; Kim NH; Park SH; Kim CD; Kim YL
Kidney Blood Press Res; 2013; 37(4-5):259-68. PubMed ID: 24022228
[TBL] [Abstract][Full Text] [Related]
44. Comparing the efficacy of continuous erythropoietin receptor activator and darbepoetin Alfa treatments in Japanese patients with chronic kidney disease during the predialysis period: A propensity-matched analysis.
Koibuchi K; Miyagi M; Arai T; Aoki T; Aikawa A; Sakai K
Nephrology (Carlton); 2015 Dec; 20 Suppl 4():22-8. PubMed ID: 26456234
[TBL] [Abstract][Full Text] [Related]
45. Simplifying anemia management in hemodialysis patients: ESAs administered at longer dosing intervals can enhance opportunities to provide patient-focused care.
Schiller B; Besarab A
Curr Med Res Opin; 2011 Aug; 27(8):1539-50. PubMed ID: 21682552
[TBL] [Abstract][Full Text] [Related]
46. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
Mahajan S; Boulton H; Gokal R
J Nephrol; 2004; 17(5):687-92. PubMed ID: 15593036
[TBL] [Abstract][Full Text] [Related]
47. Renal anemia: comparing current Eastern and Western European management practice (ORAMA).
Wiecek A; Covic A; Locatelli F; Macdougall IC;
Ren Fail; 2008; 30(3):267-76. PubMed ID: 18350446
[TBL] [Abstract][Full Text] [Related]
48. Estimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient population.
Sharma A; Yee J; Gandra SR; Khan I; Petersen J
Curr Med Res Opin; 2010 Nov; 26(11):2679-87. PubMed ID: 20942616
[TBL] [Abstract][Full Text] [Related]
49. Individualizing decision-making--resurrecting the doctor-patient relationship in the anemia debate.
Agarwal R
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1340-6. PubMed ID: 20448071
[TBL] [Abstract][Full Text] [Related]
50. Erythropoietic response and outcomes in kidney disease and type 2 diabetes.
Solomon SD; Uno H; Lewis EF; Eckardt KU; Lin J; Burdmann EA; de Zeeuw D; Ivanovich P; Levey AS; Parfrey P; Remuzzi G; Singh AK; Toto R; Huang F; Rossert J; McMurray JJ; Pfeffer MA;
N Engl J Med; 2010 Sep; 363(12):1146-55. PubMed ID: 20843249
[TBL] [Abstract][Full Text] [Related]
51. Novel erythropoiesis stimulating protein for managing the anemia of chronic kidney disease.
Nissenson AR
Am J Kidney Dis; 2001 Dec; 38(6):1390-7. PubMed ID: 11728981
[TBL] [Abstract][Full Text] [Related]
52. Anemia in chronic kidney disease: causes, diagnosis, treatment.
Nurko S
Cleve Clin J Med; 2006 Mar; 73(3):289-97. PubMed ID: 16548452
[TBL] [Abstract][Full Text] [Related]
53. Association of anemia correction with health related quality of life in patients not on dialysis.
Alexander M; Kewalramani R; Agodoa I; Globe D
Curr Med Res Opin; 2007 Dec; 23(12):2997-3008. PubMed ID: 17958944
[TBL] [Abstract][Full Text] [Related]
54. Applying evidence into routine clinical care at a unit level: the exemplar of renal anaemia management.
Gallagher MP; Cass A; Craig JC
Nephrology (Carlton); 2010 Jun; 15(4):429-33. PubMed ID: 20609094
[TBL] [Abstract][Full Text] [Related]
55. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
Hoggard J; Crouch T; McMurray S; Levine M; Prathikanti R; Scarlata D; Audhya P
Curr Med Res Opin; 2006 Oct; 22(10):2023-30. PubMed ID: 17022861
[TBL] [Abstract][Full Text] [Related]
56. Optimizing the management of renal anemia: challenges and new opportunities.
Locatelli F; Del Vecchio L
Kidney Int Suppl; 2008 Dec; (111):S33-7. PubMed ID: 19034323
[TBL] [Abstract][Full Text] [Related]
57. The KDIGO anemia guideline: can reason triumph over regulation?
Wish JB
Nephrol News Issues; 2012 Dec; 26(13):20, 22-3. PubMed ID: 23346853
[No Abstract] [Full Text] [Related]
58. Initiation of anaemia management in patients with chronic kidney disease not on dialysis in the Veterans Health Administration.
Lawler EV; Gagnon DR; Fink J; Seliger S; Fonda J; Do TP; Gaziano JM; Bradbury BD
Nephrol Dial Transplant; 2010 Jul; 25(7):2237-44. PubMed ID: 20083469
[TBL] [Abstract][Full Text] [Related]
59. Transfusion burden among patients with chronic kidney disease and anemia.
Lawler EV; Bradbury BD; Fonda JR; Gaziano JM; Gagnon DR
Clin J Am Soc Nephrol; 2010 Apr; 5(4):667-72. PubMed ID: 20299366
[TBL] [Abstract][Full Text] [Related]
60. Erythropoiesis-stimulating agents in anaemia due to chronic kidney disease: a cost-minimization analysis.
Escudero-Vilaplana V; Martínez-Nieto C; López-Gómez JM; Vega-Martínez A; Bellón-Cano JM; Sanjurjo-Sáez M
Int J Clin Pharm; 2013 Jun; 35(3):463-8. PubMed ID: 23595914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]